Open AccessColistin versus Colistin Combined with Ampicillin. Sulbactam for Multiresistant Acinetobacter baumannii Ventilator. Associated Pneumonia Treatment: An Open. Label Prospective Study
Author(s) -
Demosthènes Makris,
Efi Petinaki,
Vasssiliki Tsolaki,
Efstratios Manoulakas,
Konstantinos Mantzarlis,
Olimpia Apostolopoulou,
D. Sfyras,
Epamidas Zakynthinos
Publication year - 2018
Publication title -
indian journal of critical care medicine/indian journal of critical care medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.317
H-Index - 30
eISSN - 1998-359X
pISSN - 0972-5229
DOI - 10.4103/ijccm.ijccm_302_17
Subject(s) - colistin , medicine , acinetobacter baumannii , ventilator associated pneumonia , sulbactam , antibiotics , ampicillin , odds ratio , prospective cohort study , pneumonia , intensive care unit , surgery , antibiotic resistance , microbiology and biotechnology , pseudomonas aeruginosa , imipenem , genetics , bacteria , biology
Retrospective studies have reported good clinical success rates using colistin as monotherapy to treat Acinetobacter baumannii ventilator-associated pneumonia (VAP), comparable to that obtained with colistin combined with other antibiotics. However, inadequate penetration into the pulmonary parenchyma for colistin has been shown in animal models.